6.20
-0.14(-2.21%)
Currency In USD
| Previous Close | 6.34 |
| Open | 6.3 |
| Day High | 6.3 |
| Day Low | 5.91 |
| 52-Week High | 3,500.42 |
| 52-Week Low | 5.55 |
| Volume | 183,696 |
| Average Volume | 160,122 |
| Market Cap | 3.61M |
| PE | 0 |
| EPS | -2,258.79 |
| Moving Average 50 Days | 7.08 |
| Moving Average 200 Days | 8.76 |
| Change | -0.14 |
If you invested $1000 in Aclarion, Inc. (ACON) since IPO date, it would be worth $0.02 as of December 20, 2025 at a share price of $6.2. Whereas If you bought $1000 worth of Aclarion, Inc. (ACON) shares 2 years ago, it would be worth $0.12 as of December 20, 2025 at a share price of $6.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
GlobeNewswire Inc.
Dec 04, 2025 1:00 PM GMT
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case studySpecial Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes over 150 articles annually represen
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managemen
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
GlobeNewswire Inc.
Nov 05, 2025 11:00 AM GMT
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers